GlassScriptPhysician profile
Mayra Derupe
NPI 1942783410
$4,317.57
in general payments reported to CMS, 2019-2025
18 companies · $927 in 2025
The $927 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $656 · 2022: $980 · 2023: $922 · 2024: $833 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.52 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,298.19 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $538.41 | 2021-2025 | Ocaliva |
| Redhill Biopharma INC. | $424.03 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Ardelyx, INC. | $357.15 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $235.44 | 2021-2023 | |
| Janssen Biotech, INC. | $235.25 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $207.66 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.37 | 2021-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $143.61 | 2023-2025 | Wegovy |
| Madrigal Pharmaceuticals | $142.62 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $140.38 | 2022 | |
| Pharmacosmos Therapeutics INC. | $123.97 | 2023 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $122.23 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $74.83 | 2024-2025 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $43.66 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $37.97 | 2024 | |
| Merck Sharp & Dohme LLC | $22.48 | 2024 | |
| Gilead Sciences, INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayra Derupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.